================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 30, 2004
HAEMONETICS CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 1-10730 04-2882273
---------------------------- ---------------- -------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
400 Wood Road Braintree, MA 02184
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 848-7100
--------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item. 5 OTHER EVENTS AND REGULATION FD DISCLOSURE
On July 30, 2004, Haemonetics Corporation, (the "Company") announced the
reelection of Dr. Yutaka Sakurada to the Company's Board of Directors. Dr.
Harvey Klein withdrew his name from the slate of candidates to be elected
to the Board in response to a recently announced policy by National
Institutes of Health ("NIH") against having NIH employees serve on
for-profit boards. Dr. Klein serves as the Chief of the Department of
Transfusion medicine at the Warren G. Magnuson Clinical Center of NIH.
Item. 7 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1: Press Release of Haemonetics Corporation dated July 30, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
(Registrant)
Date: July 30, 2004 By: /s/ Ronald J. Ryan
----------------------------------
Ronald J. Ryan, Vice President and
Chief Financial Officer
2
EXHIBIT INDEX
Exhibit No. Subject Matter
99.1 Press Release of Haemonetics Corporation dated July 30, 2004.
3